Just as a reminder. In the May 1st issue of
@TheLancetOncol
- Arndt Vogel & colleagues report the results from the phase 2 FIGHT2️⃣0️⃣2️⃣ trial. Impressive activity of pemigatinib in
#cholangiocarcinoma
w. FGFR2 fusios/rearrangements.
#OncoAlert
🚨
1
18
43
Replies
@BenWestphalen
@TheLancetOncol
@pashtoonkasi
@realbowtiedoc
Are the 'other alterations' detailed somewhere?( i.e. whether they are activating vs VUS mutations, or even AMP) Can not find that info
1
0
0